Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy

Article ID	Journal	Published Year	Pages	File Type
7780277	Bioorganic & Medicinal Chemistry Letters	2018	8 Pages	PDF

Keywords

ECM DBM GLP BuOH AUC0-t CDCl3 PDGF CCR2 Diabetes model ACR UUO LC-MS PFD Unilateral ureteral occlusion N-butanol CCR TGF-β NIH3T3 Cmax LPS DMF GSI SAR GC-MS DMSO MTT NOx N,N-dimethylformamide ROS Infrared radiation peak concentration transforming growth factor-β ELISA Enzyme-linked immunosorbent assay BUN Dimethyl sulfoxide Structure activity relationships Anti-fibrosis Anti-inflammatory Pharmacodynamics Pharmacokinetics platelet-derived growth factor TNF-α lipopolysaccharide Extracellular matrix end stage renal disease area under the curve Creatinine clearance rate Albumin-to-creatinine ratio Diabetic nephropathy blood urea nitrogen nicotinamide adenine dinucleotide phosphate oxidase HMBC یا Heteronuclear Multiple Bond Correlation heteronuclear multiple bond correlation Pirfenidone Multi-target serum creatinine high performance liquid chromatography HPLC Reactive oxygen species SCR

Related Topics

Physical Sciences and Engineering Chemistry Organic Chemistry

Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy

Authors

Jun Chen, Zhangzhe Peng, Miaomiao Lu, Xuan Xiong, Zhuo Chen, Qianbin Li, Zeneng Cheng, Dejian Jiang, Lijian Tao, Gaoyun Hu,